• John C. Kappes (b. 1957), Associate Professor of Medicine and Microbiology, completed his undergraduate studies in biology at Thomas More College (B.A. in Biology, 1981) and received his Ph.D. in Microbiology and Experimental Medicine from St. Thomas Institute in 1986. Dr. Kappes completed his postdoctoral fellowship studying the molecular pathogenesis of human immunodeficiency viruses and joined the UAB faculty in 1989.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse modelScience Translational Medicine.  11. 2019
    2019 Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R)Molecular and Cellular Endocrinology.  492. 2019
    2017 Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodiesScience Translational Medicine.  9. 2017
    2017 Dendritic cells from the human female reproductive tract rapidly capture and respond to HIVMucosal Immunology.  10:531-544. 2017
    2017 Evaluation of the contribution of the transmembrane region to the ectodomain conformation of the human immunodeficiency virus (HIV-1) envelope glycoproteinVirology Journal.  14. 2017
    2017 Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscsPLoS ONE.  12. 2017
    2017 The transcriptome of HIV-1 infected intestinal CD4+ T cells exposed to enteric bacteriaPLoS Pathogens.  13. 2017
    2017 Substitution of Yor1p NBD1 residues improves the thermal stability of human cystic fibrosis transmembrane conductance regulatorProtein Engineering -Oxford-.  30:729-741. 2017
    2016 Expression and purification of the alpha subunit of the epithelial sodium channel, ENaCProtein Expression and Purification.  117:67-75. 2016
    2016 Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanomaOncotarget.  7:1227-1241. 2016
    2016 High-throughput humanized mouse models for evaluation of HIV-1 therapeutics and pathogenesisMethods in Molecular Biology.  1354:221-235. 2016
    2016 Inhibition of NADPH oxidase 1 activity and blocking the binding of cytosolic and membrane-bound proteins by honokiol inhibit migratory potential of melanoma cellsOncotarget.  7:7899-7912. 2016
    2015 A Stable Human-Cell System Overexpressing Cystic Fibrosis Transmembrane Conductance Regulator Recombinant Protein at the Cell SurfaceMolecular Biotechnology.  57:391-405. 2015
    2015 Erratum to: A Stable Human-Cell System Overexpressing Cystic Fibrosis Transmembrane Conductance Regulator Recombinant Protein at the Cell Surface [Mol Biotechnol, DOI 10.1007/s12033-014-9830-5]Molecular Biotechnology.  57:406. 2015
    2014 Erratum: Resveratrol Enhances Airway Surface Liquid Depth in Sinonasal Epithelium by Increasing Cystic Fibrosis Transmembrane Conductance Regulator Open Probability (PLoS ONE (2014) 9:1 (DOI:10.1371/annotation/d852ff1d-2824- 4f4d-80f2-9be7a42a5f25))PLoS ONE.  9. 2014
    2014 Membrane protein stability can be compromised by detergent interactions with the extramembranous soluble domainsProtein Science.  23:769-789. 2014
    2013 Relative resistance of HIV-1 founder viruses to control by interferon-alphaRetrovirology.  10. 2013
    2013 Impact of HIV-1 backbone on neutralization sensitivity: Neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01-AE backbonePLoS ONE.  8. 2013
    2013 Detection of HIV-1 neutralizing antibodies in a human CD4 +/CXCR4+/CCR5+ T-lymphoblastoid cell assay systemPLoS ONE.  8. 2013
    2013 Resveratrol enhances airway surface liquid depth in sinonasal epithelium by increasing cystic fibrosis transmembrane conductance regulator open probabilityPLoS ONE.  8. 2013
    2013 Lyn Facilitates Glioblastoma Cell Survival under Conditions of Nutrient Deprivation by Promoting AutophagyPLoS ONE.  8. 2013
    2013 Mice Transgenic for CD4-Specific Human CD4, CCR5 and Cyclin T1 Expression: A New Model for Investigating HIV-1 Transmission and Treatment EfficacyPLoS ONE.  8. 2013
    2013 Phenotypic properties of transmitted founder HIV-1Proceedings of the National Academy of Sciences.  110:6626-6633. 2013
    2013 Optimization of the transductional efficiency of lentiviral vectors: Effect of sera and polycationsMolecular Biotechnology.  53:308-314. 2013
    2013 Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clonesVirology.  436:33-48. 2013
    2012 HIV-1 Expressing the Envelopes of Transmitted/Founder or Control/Reference Viruses Have Similar Infection Patterns of CD4 T-Cells in Human Cervical Tissue Ex VivoPLoS ONE.  7. 2012
    2012 Selective impact of HIV disease progression on the innate immune system in the human female reproductive tractPLoS ONE.  7. 2012
    2012 Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7PLoS Pathogens.  8. 2012
    2012 The role of natural killer (NK) cells and nk cell receptor polymorphisms in the assessment of HIV-1 neutralizationPLoS ONE.  7. 2012
    2012 Purification of CFTR for mass spectrometry analysis: Identification of palmitoylation and other post-translational modificationsProtein Engineering -Oxford-.  25:7-14. 2012
    2011 Stromal down-regulation of macrophage CD4/CCR5 expression and NF-κB activation mediates HIV-1 non-permissiveness in intestinal macrophagesPLoS Pathogens.  7. 2011
    2011 Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent mannerNeuro-Oncology.  13:28-41. 2011
    2010 Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMCVirology.  408:1-13. 2010
    2010 Uterine epithelial cell regulation of DC-SIGN expression inhibits transmitted/founder HIV-1 trans infection by immature dendritic cellsPLoS ONE.  5. 2010
    2010 Anti-HIV activity in cervical-vaginal secretions from HIV-Positive and -Negative women correlate with innate antimicrobial levels and IgG antibodiesPLoS ONE.  5. 2010
    2009 P04-12. Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assaysRetrovirology.  6. 2009
    2009 P04-23. HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specificRetrovirology.  6. 2009
    2009 P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopesRetrovirology.  6. 2009
    2009 P20-15. Evaluation of HIV-1 subtype B acute envelope-expressing infectious molecular clonesRetrovirology.  6. 2009
    2009 S01-04 OA. Phenotypic analyses of CD8+ T cells that mediate virus inhibition from HIV-1 vaccinees and HIV-1+ virus controllersRetrovirology.  6. 2009
    2009 Clinical and molecular characterization of S1118F-CFTRPediatric Pulmonology.  44:1003-1009. 2009
    2007 Neural progenitor cell transplantation and imaging in a large animal modelNeuroscience Research.  59:327-340. 2007
    2006 Tethering KSRP, a decay-promoting AU-rich element-binding protein, to mRNAs elicits mRNA decayMolecular and Cellular Biology.  26:3695-3706. 2006
    2003 Erratum: Antibody neutralization and escape by HIV-1 (Nature (2003) 422 (307-312))Nature.  423:197. 2003
    2003 Antibody neutralization and escape by HIV-1Nature.  422:307-312. 2003
    2003 Production of trans-lentiviral vector with predictable safety.Methods in Molecular Medicine.  76:449-465. 2003
    2002 Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cellsNature Medicine.  8:150-156. 2002
    2001 Safety considerations in vector developmentSomatic Cell and Molecular Genetics.  26:147-158. 2001
    2001 Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1Nature Medicine.  7:920-926. 2001
    2000 Development of a novel trans-lentiviral vector that affords predictable safetyMolecular Therapy.  2:47-55. 2000
    2000 Lentiviral vector transduction of hematopoietic stem cells that mediate long-term reconstitution of lethally irradiated miceSTEM CELLS.  18:352-359. 2000
    1996 Proteolytic activity of human immunodeficiency virus Vpr-and Vpx-protease fusion proteinsVirology.  219:307-313. 1996
    1993 A Short-Term Clinical Evaluation of L-697,661, a Non-Nucleoside Inhibitor of HIV-1 Reverse TranscriptaseNew England Journal of Medicine.  329:1065-1072. 1993
    1993 High levels of HIV-1 in plasma during all stages of infection determined by competitive PCRScience.  259:1749-1754. 1993
    1993 Intracellular transport and virion incorporation of vpx requires interaction with other virus type-specific componentsVirology.  193:222-233. 1993
    1991 High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infectionNew England Journal of Medicine.  324:954-960. 1991
    1991 Human immunodeficiency virus type 2 vpx protein augments viral infectivityVirology.  184:197-209. 1991
    1988 West African HIV-2-related human retrovirus with attenuated cytopathicityScience.  240:1525-1529. 1988

    Research Overview

  • Dr. Kappes' research is focused on studying the molecular biology of the human immunodeficiency virus type 1 (HIV-1), and the development of lentiviral-based vectors for gene delivery. These studies are helping to understand how infectious virions are formed and how the viral enzymes [reverse transcriptase (RT) and integrase (IN)], function during the early stages of the virus life cycle. By using virion associated HIV accessory proteins (Vpr and Vpx), Dr. Kappes has developed an approach for incorporating functional RT and IN into virions independently of the normal Gag-Pol packaging pathway. This has uncoupled the RT and IN function from Gag-Pol function and enabled, for the first time, a detailed molecular analysis of reverse transcription and integration in the context of replicating virus (in vivo). Based on the principles of incorporating RT and IN in trans, Dr. Kappes has developed a new generation of HIV/lentiviral-based vectors for gene therapy. Lentiviral vectors appear to be well suited for gene therapy since they can transduce nondividing (somatic) cells. By separating the expression of RT and IN from the other vector components it is possible to produce lentiviral vectors with minimal risk of recombination and the generation of replication competent virus.
  • Investigator On

  • CA-VIMC Molecular Virology Core (UAB)  awarded by Duke University 2016 - 2021
  • Virologic Strategies for ADVANCEd lmmunoAssays  awarded by INTERNATIONAL AIDS VACCINE INITIATIVE 2016 - 2020
  • A Novel Role for IGF-1 Receptor in Growth Hormone Action  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2019
  • Pathogenesis of Rebound SIV/HIV Viremia After Antiretroviral Therapy  awarded by Northwestern University 2017 - 2019
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2014 - 2019
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • UAB CF Research and Translation Core Center - Core A: Cell Model and Assay Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2015 - 2018
  • A Comprehensive Evaluation of Microgravity Protein Crystallization  awarded by NASA - National Aeronautics & Space Administration 2011 - 2016
  • Innovative Solutions Toward a 3D CFTR Structure  awarded by Cystic Fibrosis Foundation 2013 - 2016
  • Vaginal Dendritic Cells Selectively Transmit HIV-1 Founder Virus  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2013 - 2016
  • CTVIMC2 - Discovery VIA Project and Clinical Trial Testing Core  awarded by Imperial College of Science, Technology & Medicine 2015 - 2016
  • UAB CF Research and Translation Core Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2012 - 2016
  • UAB CF Research and Translation Core Center - Core A  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2012 - 2016
  • Production & Crystallization of Membrane Protein for 3D Structure  awarded by National Institute of General Medical Sciences/NIH/DHHS 2010 - 2015
  • UAB Center for AIDS Research  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2009 - 2014
  • Crystallization and Structure Determination of Full-Length CFTR Protein  awarded by Cystic Fibrosis Foundation 2005 - 2013
  • Mucosal HIV and Immunobiology Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2008 - 2013
  • CHAVI - Center for HIV/AIDS Vaccine Immunology  awarded by Duke University 2005 - 2012
  • Development of a Robust PBMC-Based HIV-1 Neutralizing Antibody Assay: Generation of Reference Env-Containing Renilla Luciferase Reporter Back Bone Proviral DNA Reagents and Methods.  awarded by Duke University 2008 - 2011
  • Full Name

  • John Kappes